2型糖尿病治療薬の世界市場予測・分析

◆英語タイトル:PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025
◆商品コード:GDHC128PIDR
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月1日
◆ページ数:476
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD10,995 ⇒換算¥1,253,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD21,990 ⇒換算¥2,506,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD32,985 ⇒換算¥3,760,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、2型糖尿病治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・2型糖尿病の概要:病因、病態生理、症状
・疫学:リスク要因、併存症、グローバル動向、予測方法、疫学的予測結果
・2型糖尿病の管理:治療概要、主要国における診断、診療状況
・2型糖尿病治療薬の競争状況:製品概要、主要医薬品ブランド分析
・2型糖尿病治療薬市場機会及びアンメット・ニーズ分析
・2型糖尿病治療薬のパイプライン分析:主要国別治験動向、フェーズ別/進捗状況別治験動向、有望な薬剤
・製薬企業動向:戦略動向、主要企業情報
・2型糖尿病治療薬市場展望:世界市場及び主要国の市場規模予測、成長要因、阻害要因
【レポートの概要】

PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025

Summary

The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the type 2 diabetes market will experience a shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class will occur; while dipeptidyl peptidase-4 inhibitors (DPP-4Is) will continue to grow, but at a much slower rate than previous years. GLP-1RAs and SGLT-2Is will experience the fastest growth of all classes at a CAGR of 12.2% and 13.0% respectively.

Highlights

Key Questions Answered

- Although the T2D market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the T2D market?
- The late-stage T2D pipeline is heavily populated with me-too drugs from the classes of GLP-1RAs, DPP-4Is, and SGLT-2Is. Despite this, an oral GLP-1RA formulation and an osmotic pump which delivers subcutaneous exenatide for one year at a time are expected to be game changers in the GLP-1RA class. Both are in Phase III clinical trials and are expected to increase compliance among T2D patients. Will the late-stage drugs make a significant impact on the T2D market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The diagnosed prevalence of T2D in the world skyrocketed in the past 10 years and will continue increasing at the fast pace. How will epidemiological changes impact the growth of the future market?

Key Findings

- The main driver of the enormous expansion of the T2D market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.
- The second largest driver will be the physicians’ efforts to delay disease progression through the use of combination therapies and novel branded drugs.
- With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs.
- In the future, companies will have to shift their focus towards competitive pricing, “niche” drugs aimed at smaller patient groups, and drugs that increase patient compliance (through more convenient administration).
- To date, no drug has demonstrated sustainable efficacy in the treatment of T2D. This unmet need presents a large opportunity for investment by drug developers.

Scope

- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T2D therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 25
2 Introduction 27
2.1 Catalyst 27
2.2 Related Reports 28
3 Disease Overview 29
3.1 Etiology 30
3.2 Pathophysiology 31
3.3 Prognosis 33
3.4 Quality of Life 33
3.5 Symptoms 34
4 Epidemiology 36
4.1 Disease Background 36
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 38
4.3.1 US 38
4.3.2 5EU 38
4.3.3 Japan 39
4.3.4 China and India 39
4.4 Forecast Methodology 40
4.4.1 Sources Used for Diagnosed Prevalence of T2D 45
4.4.2 Sources Not Used 56
4.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of T2D 57
4.5 Epidemiological Forecast for T2D (2015-2025) 68
4.5.1 Diagnosed Prevalent Cases of T2D 68
4.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 70
4.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 72
4.5.4 Age-Standardized Diagnosed Prevalence of T2D 74
4.5.5 Prevalent Cases of Chronic Kidney Disease Among Diagnosed T2D Cases 76
4.5.6 Prevalent Cases of Cardiovascular Disease Among Diagnosed T2D Cases 76
4.5.7 Prevalent Cases of Overweight/Obesity Among Diagnosed T2D Cases 77
4.5.8 Prevalent Cases of Hypertension Among Diagnosed T2D Cases 78
4.5.9 Prevalent Cases of Dyslipidemia Among Diagnosed T2D Cases 79
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 81
4.6.3 Strengths of the Analysis 81
5 Disease Management 83
5.1 Treatment Overview 83
5.1.1 Diagnosis and Referrals 83
5.1.2 Treatment Guidelines and Leading Prescribed Therapies 84
5.1.3 Clinical Practice 89
5.2 US 90
5.3 France 93
5.4 Germany 96
5.5 Italy 99
5.6 Spain 105
5.7 UK 108
5.8 Japan 113
5.9 China 116
5.10 India 119
6 Competitive Assessment 122
6.1 Overview 122
6.2 Strategic Competitor Assessment 122
6.3 Product Profiles – Major Brands 125
6.3.1 Metformin 125
6.3.2 Sulfonylureas and Other Insulin Secretagogues 130
6.3.3 α-glucosidase Inhibitors 135
6.3.4 Thiazolidinediones 139
6.3.5 Glucagon-Like Peptide-1 Receptor Agonists 144
6.3.6 Dipeptidyl-Peptidase 4 Inhibitors 176
6.3.7 Sodium-Glucose Cotransporter 2 Inhibitors 214
6.3.8 Insulin Formulations 238
7 Unmet Needs and Opportunities 270
7.1 Overview 270
7.2 Disease-Modifying Treatments Providing Sustained Glycemic Control 271
7.2.1 Unmet Need 271
7.2.2 Gap Analysis 272
7.2.3 Opportunity 272
7.3 Drugs with Non-Glycemic Benefits 273
7.3.1 Unmet Need 273
7.3.2 Gap Analysis 273
7.3.3 Opportunity 274
7.4 Drugs with Improved Side-Effect Profiles 274
7.4.1 Unmet Need 274
7.4.2 Gap Analysis 275
7.4.3 Opportunity 275
7.5 Increased Patient Compliance 275
7.5.1 Unmet Need 275
7.5.2 Gap Analysis 276
7.5.3 Opportunity 277
8 Pipeline Assessment 278
8.1 Overview 278
8.2 Clinical Trial Mapping 279
8.2.1 Clinical Trials by Country 279
8.2.2 Clinical Trials by Phase and Trial Status 279
8.3 Promising Drugs in Clinical Development 280
8.3.1 Semaglutide 283
8.3.2 OG217SC/Semaglutide (oral) 287
8.3.3 ITCA 650 291
8.3.4 Marizev (omarigliptin) 295
8.3.5 Ertugliflozin 299
8.3.6 FIAsp 303
8.3.7 Biosimilar Insulins 305
9 Current and Future Players 314
9.1 Overview 314
9.2 Trends in Corporate Strategy 318
9.3 Company Profiles 320
9.3.1 Eli Lilly 320
9.3.2 Novo Nordisk 323
9.3.3 Sanofi 326
9.3.4 GlaxoSmithKline 329
9.3.5 AstraZeneca 331
9.3.6 Merck & Co. 333
9.3.7 Boehringer Ingelheim 335
9.3.8 Takeda 336
9.3.9 Roche 338
9.3.10 Pfizer 340
9.3.11 Johnson & Johnson 341
9.3.12 Novartis 343
9.3.13 Intarcia Therapeutics 344
10 Market Outlook 346
10.1 Global Markets 346
10.1.1 Forecast 346
10.1.2 Drivers and Barriers – Global Issues 353
10.2 US 354
10.2.1 Forecast 354
10.2.2 Key Events 359
10.2.3 Drivers and Barriers 360
10.3 France 362
10.3.1 Forecast 362
10.3.2 Key Events 367
10.3.3 Drivers and Barriers 367
10.4 Germany 369
10.4.1 Forecast 369
10.4.2 Key Events 373
10.4.3 Drivers and Barriers 373
10.5 Italy 375
10.5.1 Forecast 375
10.5.2 Key Events 379
10.5.3 Drivers and Barriers 379
10.6 Spain 381
10.6.1 Forecast 381
10.6.2 Key Events 385
10.6.3 Drivers and Barriers 385
10.7 UK 387
10.7.1 Forecast 387
10.7.2 Key Events 391
10.7.3 Drivers and Barriers 391
10.8 Japan 393
10.8.1 Forecast 393
10.8.2 Key Events 398
10.8.3 Drivers and Barriers 398
10.9 China 400
10.9.1 Forecast 400
10.9.2 Key Events 404
10.9.3 Drivers and Barriers 405
10.10 India 406
10.10.1 Forecast 406
10.10.2 Key Events 411
10.10.3 Drivers and Barriers 411
11 Appendix 414
11.1 Bibliography 414
11.2 Abbreviations 447
11.3 Methodology 455
11.4 Forecasting Methodology 455
11.4.1 Diagnosed T2D Patients 455
11.4.2 Percent Drug-Treated Patients 455
11.4.3 Drugs Included in Each Therapeutic Class 455
11.4.4 Launch and Patent Expiry Dates 456
11.4.5 General Pricing Assumptions 457
11.4.6 Individual Drug Assumptions 458
11.4.7 Generic Erosion 468
11.4.8 Pricing of Pipeline Agents 468
11.5 Physicians and Specialists Included in this Study 469
11.6 About the Authors 472
11.6.1 Analyst – CVMD 472
11.6.2 Director – CVMD 472
11.6.3 Epidemiologist 473
11.6.4 Global Director of Therapy Analysis and Epidemiology 473
11.6.5 Global Head of Healthcare 474
11.7 About GlobalData 475
11.8 Disclaimer 475

1.1 List of Tables
Table 1: T2D Pathophysiology 32
Table 2: Symptoms of T2D 35
Table 3: Risk Factors and Comorbidities for T2D 37
Table 4: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D 41
Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D 42
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D 42
Table 7: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D 43
Table 8: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D 44
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D 44
Table 10: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025 69
Table 11: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015 71
Table 12: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N (Row %), 2015 73
Table 13: Diagnostic Tests and Typical Criteria for T2D 83
Table 14: T2D Treatments 86
Table 15: Country Profile, T2D Management - US 92
Table 16: Country Profile, T2D Management - France 95
Table 17: Country Profile, T2D Management - Germany 98
Table 18: Country Profile, T2D Management - Italy 103
Table 19: Country Profile, T2D Management - Spain 107
Table 20: Country Profile, T2D Management - UK 112
Table 21: Country Profile, T2D Management - Japan 115
Table 22: Country Profile, T2D Management - China 118
Table 23: Country Profile, T2D Management - India 120
Table 24: Leading Branded Treatments for T2D, 2015 124
Table 25: Product Profile - Metformin 127
Table 26: Metformin SWOT Analysis, 2015 129
Table 27: Global Sales Forecasts ($M) for Metformin, 2015-2025 130
Table 28: First-Generation SUs 131
Table 29: Second-Generation SUs 132
Table 30: Product Profile - SUs 132
Table 31: SUs SWOT Analysis, 2015 134
Table 32: Global Sales Forecasts ($M) for SUs and non-SUs, 2015-2025 135
Table 33: Product Profile - Acarbose 136
Table 34: AGIs SWOT Analysis, 2015 138
Table 35: Global Sales Forecasts ($M) for AGIs, 2015-2025 139
Table 36: Product Profile - Actos 141
Table 37: TZDs SWOT Analysis, 2015 143
Table 38: Global Sales Forecasts ($M) for TZDs, 2015-2025 144
Table 39: GLP-1RAs 146
Table 40: Product Profile - Byetta 148
Table 41: Byetta SWOT Analysis, 2015 150
Table 42: Global Sales Forecasts ($M) for Byetta, 2015-2025 151
Table 43: Product Profile - Victoza 152
Table 44: Victoza SWOT Analysis, 2015 155
Table 45: Global Sales Forecasts ($M) for Victoza, 2015-2025 156
Table 46: Product Profile - Bydureon 157
Table 47: Bydureon SWOT Analysis, 2015 159
Table 48: Global Sales Forecasts ($M) for Bydureon, 2015-2025 160
Table 49: Product Profile - Lyxumia 162
Table 50: Lyxumia SWOT Analysis, 2015 164
Table 51: Global Sales Forecasts ($M) for Lyxumia, 2015-2025 165
Table 52: Product Profile - Tanzeum 167
Table 53: Tanzeum SWOT Analysis, 2015 170
Table 54: Global Sales Forecasts ($M) for Tanzeum, 2015-2025 171
Table 55: Product Profile - Trulicity 172
Table 56: Trulicity SWOT Analysis, 2015 175
Table 57: Global Sales Forecasts ($M) for Trulicity, 2015-2025 176
Table 58: Marketed DPP-4Is 179
Table 59: Marketed DPP-4Is in Combination with Other OADs 179
Table 60: Product Profile - Januvia 181
Table 61: Januvia SWOT Analysis, 2015 183
Table 62: Global Sales Forecasts ($M) for Januvia, Janumet, Janumet XR, 2015-2025 184
Table 63: Product Profile - Onglyza 186
Table 64: Onglyza SWOT Analysis, 2015 188
Table 65: Global Sales Forecasts ($M) for Onglyza, Kombiglyze, XR, 2015-2025 189
Table 66: Product Profile - Tradjenta 190
Table 67: Tradjenta SWOT Analysis, 2015 192
Table 68: Global Sales Forecasts ($M) for Tradjenta, Jentadueto, 2015-2025 193
Table 69: Product Profile - Galvus 195
Table 70: Galvus SWOT Analysis, 2015 197
Table 71: Global Sales Forecasts ($M) for Galvus, Eucreas, 2015-2025 198
Table 72: Product Profile - Nesina 200
Table 73: Nesina SWOT Analysis, 2015 202
Table 74: Global Sales Forecasts ($M) for Nesina, Oseni, Kazano, 2015-2025 203
Table 75: Product Profile - Tenelia 204
Table 76: Tenelia SWOT Analysis, 2015 206
Table 77: Global Sales Forecasts ($M) for Tenelia, 2015-2025 207
Table 78: Product Profile - Suiny 208
Table 79: Suiny SWOT Analysis, 2015 209
Table 80: Global Sales Forecasts ($M) for Suiny, 2015-2025 210
Table 81: Product Profile - Zafatek 211
Table 82: Zafatek SWOT Analysis, 2015 213
Table 83: Global Sales Forecasts ($M) for Zafatek, 2015-2025 214
Table 84: SGLT-2Is 215
Table 85: Marketed SGLT-2Is in Combination with Other T2D Drugs 216
Table 86: Product Profile - Forxiga 217
Table 87: Forxiga SWOT Analysis, 2015 219
Table 88: Global Sales Forecasts ($M) for Forxiga, Xigduo XR, SaxaDapa, SaxaDapa + metformin, 2015-2025 220
Table 89: Product Profile - Invokana 221
Table 90: Invokana SWOT Analysis, 2015 223
Table 91: Global Sales Forecasts ($M) for Invokana, InvokaMet, XR, IR, 2015-2025 224
Table 92: Product Profile - Jardiance 225
Table 93: Jardiance SWOT Analysis, 2015 227
Table 94: Global Sales Forecasts ($M) for Jardiance, Synjardy, Glyxambi, 2015-2025 228
Table 95: Product Profile - Apleway 229
Table 96: Apleway SWOT Analysis, 2015 231
Table 97: Global Sales Forecasts ($M) for Apleway, 2015-2025 232
Table 98: Product Profile - Suglat 233
Table 99: Suglat SWOT Analysis, 2015 234
Table 100: Global Sales Forecasts ($M) for Suglat, 2015-2025 235
Table 101: Product Profile - Lusefi 236
Table 102: Lusefi SWOT Analysis, 2015 237
Table 103: Global Sales Forecasts ($m) for Lusefi, 2015-2025 238
Table 104: Insulins - Overview and Comparison 239
Table 105: Insulin Formulations 240
Table 106: Product Profile - Humalog 241
Table 107: Humalog SWOT Analysis, 2015 242
Table 108: Global Sales Forecasts ($M) for Humalog, Humalog Mixes, Humalog 200U, 2015-2025 243
Table 109: Product Profile - Lantus 245
Table 110: Lantus SWOT Analysis, 2015 248
Table 111: Global Sales Forecasts ($M) for Lantus, Toujeo LixiLan, 2015-2025 249
Table 112: Toujeo SWOT Analysis, 2015 252
Table 113: Product Profile - Levemir 253
Table 114: Levemir SWOT Analysis, 2015 255
Table 115: Global Sales Forecasts ($M) for Levemir, 2015-2025 256
Table 116: Product Profile - NovoLog 257
Table 117: NovoLog SWOT Analysis, 2015 258
Table 118: Global Sales Forecasts ($M) for NovoRapid, NovoMix, FIAsp, 2015-2025 259
Table 119: Product Profile - Apidra 260
Table 120: Apidra SWOT Analysis, 2015 261
Table 121: Global Sales Forecasts ($M) for Apidra, 2015-2025 262
Table 122: Product Profile - Tresiba 263
Table 123: Tresiba SWOT Analysis, 2015 264
Table 124: Global Sales Forecasts ($M) for Tresiba, Xultophy, Ryzodeg, 2015-2025 265
Table 125: Product Profile - Afrezza 267
Table 126: Afrezza SWOT Analysis, 2015 268
Table 127: Global Sales Forecasts ($M) for Afrezza, 2015-2025 269
Table 128: Unmet Needs and Opportunities in T2D 271
Table 129: T2D - Clinical Trials by Phase and Status, 2015 280
Table 130: T2D - Phase Pipeline, 2015 282
Table 131: Comparison of Therapeutic Classes in Development for T2D, 2015 282
Table 132: Product Profile - Semaglutide 284
Table 133: Semaglutide SWOT Analysis, 2015 286
Table 134: Global Sales Forecasts ($M) for Semaglutide, 2015-2025 287
Table 135: Product Profile - OG217SC 288
Table 136: OG217SC SWOT Analysis, 2015 290
Table 137: Global Sales Forecasts ($M) for OG217SC, 2015-2025 290
Table 138: Product Profile - ITCA 650 291
Table 139: ITCA-650 SWOT Analysis, 2015 294
Table 140: Global Sales Forecasts ($M) for ITCA-650, 2015-2025 294
Table 141: Product Profile - Marizev 296
Table 142: Marizev SWOT Analysis, 2015 298
Table 143: Global Sales Forecasts ($M) for Marizev, 2015-2025 299
Table 144: Product Profile - Ertugliflozin 300
Table 145: Ertugliflozin SWOT Analysis, 2015 302
Table 146: Global Sales Forecasts ($M) for Ertugliflozin, Ertugliflozin + metformin, Sitagliptin + Ertugliflozin, 2015-2025 303
Table 147: Product Profile - FIAsp 304
Table 148: FIAsp SWOT Analysis, 2015 305
Table 149: Product Profile - Abasaglar 310
Table 150: Abasaglar SWOT Analysis, 2015 312
Table 151: Global Sales Forecasts ($M) for Abasaglar, 2015-2025 313
Table 152: Key Companies in the T2D Market, 2015 316
Table 153: Other Companies in the T2D Market, 2015 317
Table 154: Eli Lilly’s T2D Portfolio Assessment, 2015 322
Table 155: Eli Lilly SWOT Analysis, 2015 323
Table 156: Novo Nordisk’s T2D Portfolio Assessment, 2015 325
Table 157: Novo Nordisk SWOT Analysis, 2015 326
Table 158: Sanofi’s T2D Portfolio Assessment, 2015 328
Table 159: Sanofi SWOT Analysis, 2015 329
Table 160: GSK’s T2D Portfolio Assessment, 2015 330
Table 161: GSK SWOT Analysis, 2015 331
Table 162: AstraZeneca’s T2D Portfolio Assessment, 2015 332
Table 163: AstraZeneca SWOT Analysis, 2015 333
Table 164: Merck’s T2D Portfolio Assessment, 2015 334
Table 165: Merck SWOT Analysis, 2015 335
Table 166: BI’s T2D Portfolio Assessment, 2015 336
Table 167: BI SWOT Analysis, 2015 336
Table 168: Takeda’s T2D Portfolio Assessment, 2015 338
Table 169: Takeda SWOT Analysis, 2015 338
Table 170: Roche’s T2D Portfolio Assessment, 2015 339
Table 171: Roche SWOT Analysis, 2015 339
Table 172: Pfizer’s T2D Portfolio Assessment, 2015 341
Table 173: Pfizer SWOT Analysis, 2015 341
Table 174: J&J’s T2D Portfolio Assessment, 2015 342
Table 175: J&J SWOT Analysis, 2015 343
Table 176: Novartis’ T2D Portfolio Assessment, 2015 343
Table 177: Novartis SWOT Analysis, 2015 344
Table 178: Intarcia Therapeutics’ T2D Portfolio Assessment, 2015 344
Table 179: Intarcia Therapeutics SWOT Analysis, 2015 345
Table 180: Global Sales Forecasts ($M) for T2D, 2015-2025 349
Table 181: T2D Market - Drivers and Barriers, 2015 353
Table 182: Sales Forecasts ($M) for T2D in the US, 2015-2025 355
Table 183: Key Events Impacting Sales for T2D in the US, 2015-2025 359
Table 184: T2D Market - Drivers and Barriers in the US, 2015 360
Table 185: Sales Forecasts ($M) for T2D in France, 2015-2025 363
Table 186: Key Events Impacting Sales for T2D in France, 2015-2025 367
Table 187: T2D Market - Drivers and Barriers in France, 2015 367
Table 188: Sales Forecasts ($M) for T2D in Germany, 2015-2025 370
Table 189: Key Events Impacting Sales for T2D in Germany, 2015-2025 373
Table 190: T2D Market - Drivers and Barriers in Germany, 2015 373
Table 191: Sales Forecasts ($M) for T2D in Italy, 2015-2025 376
Table 192: Key Events Impacting Sales for T2D in Italy, 2015-2025 379
Table 193: T2D Market - Drivers and Barriers in Italy, 2015 379
Table 194: Sales Forecasts ($M) for T2D in Spain, 2015-2025 382
Table 195: Key Events Impacting Sales for T2D in Spain, 2015-2025 385
Table 196: T2D Market - Drivers and Barriers in Spain, 2015 385
Table 197: Sales Forecasts ($M) for T2D in the UK, 2015-2025 388
Table 198: Key Events Impacting Sales for T2D in the UK, 2015-2025 391
Table 199: T2D Market - Drivers and Barriers in the UK, 2015 391
Table 200: Sales Forecasts ($M) for T2D in Japan, 2015-2025 395
Table 201: Key Events Impacting Sales for T2D in Japan, 2015-2025 398
Table 202: T2D Market - Drivers and Barriers in Japan, 2015 398
Table 203: Sales Forecasts ($M) for T2D in China, 2015-2025 401
Table 204: Key Events Impacting Sales for T2D in China, 2015-2025 404
Table 205: T2D Market - Drivers and Barriers in China, 2015 405
Table 206: Sales Forecasts ($M) for T2D in India, 2015-2025 408
Table 207: Key Events Impacting Sales for T2D in India, 2015-2025 411
Table 208: T2D Market - Drivers and Barriers in India, 2015 411
Table 209: Key Launch Dates 456
Table 210: Key Patent Expiries 457
Table 211: Number of High-Prescribing Physicians Surveyed 471

1.2 List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025 70
Figure 2: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2015 72
Figure 3: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2015 74
Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of T2D (%), Ages ≥20 Years, by Sex, 2015 75
Figure 5: 9MM, Prevalent Cases of CKD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015 76
Figure 6: 8MM, Prevalent Cases of CVD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015 77
Figure 7: 9MM, Prevalent Cases of Overweight/Obesity Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015 78
Figure 8: 9MM, Prevalent Cases of Hypertension Among Diagnosed T2D, Both Sexes, Ages ≥20Years, N, 2015 79
Figure 9: 8MM, Prevalent Cases of Dyslipidemia Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015 80
Figure 10: Incretin and SGLT-2I Mechanisms of Action 88
Figure 11: ADA/EASD General Recommendations for Antihyperglycemic Therapy 89
Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2015-2025 283
Figure 13: Company Portfolio Gap Analysis in T2D, 2015-2025 318
Figure 14: 9MM, Global Sales for T2D by Region, 2015-2025 352
Figure 15: Sales for T2D in the US by Drug Class, 2015-2025 358
Figure 16: Sales for T2D in France by Drug Class, 2015-2025 366
Figure 17: Sales for T2D in Germany by Drug Class, 2015-2025 372
Figure 18: Sales for T2D in Italy by Drug Class, 2015-2025 378
Figure 19: Sales for T2D in Spain by Drug Class, 2015-2025 384
Figure 20: Sales for T2D in the UK by Drug Class, 2015-2025 390
Figure 21: Sales for T2D in Japan by Drug Class, 2015-2025 397
Figure 22: Sales for T2D in China by Drug Class, 2015-2025 403
Figure 23: Sales for T2D in India by Drug Class, 2015-2025 410

【掲載企業】

Eli Lilly
Novo Nordisk
Sanofi
GlaxoSmithKline
AstraZeneca
Merck & Co.
Boehringer Ingelheim
Takeda
Roche
Pfizer
Johnson & Johnson
Novartis
Intarcia Therapeutics

【レポートのキーワード】

2型糖尿病

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[2型糖尿病治療薬の世界市場予測・分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月09日現在 219,203 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆